IPSC Stock Analysis: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$2.41
0.11 (4.78%)
▲
5d:
+4.78%
30d:
+6.17%
90d:
+1.69%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IPSC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IPSC shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $2.41, which is considered extended relative to its 30-day fair value range of $2.15 to $2.34.
Technical Outlook: Technically, IPSC is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.52. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: IPSC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.75 (+97.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPSC is showing sideways momentum. Immediate support is located at $1.98, while resistance sits at $2.52. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: IPSC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.75 (+97.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.15 -
$2.34
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 97.1% below Wall St target ($4.75)
Trading Range Analysis
30-Day Trading Range
$2.15 -
$2.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$2.53
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.27
Wall Street Target
$4.75
(+97.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 23, 2026 11:01 PM ET
Data refreshes hourly during market hours. Next update: 12:01 AM
Data refreshes hourly during market hours. Next update: 12:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Gregory Russotti
SELL
10076 shares
2026-03-12
Douglas Carr
SELL
7043 shares
2026-03-12
Gregory Russotti
SELL
479 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
